AR AR alternative transcripts

CI-VAR-00000174Explore in graph →CIViC 3460

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Prostate Neoplasm2
AR AR alternative transcripts	(oncogenic)	Oncogenic	B	Supports Oncogenicity	4	submitted	EID12402 Analysing 101 samples of metastatic prostate cancer biopsy, a high friequency of structural variants in the AR gene were identified (23/101), comprising a heterogeneous mix of deletion, inversion, tra… (full text at CIViC) PMID 31932493 · Li et al., 2020 · Open in CIViC	civic
AR AR alternative transcripts	Abiraterone + EnzalutamideSubstitutes	Predictive	B	Does Not Support Resistance	4	submitted	EID9578 In a clinical study including 168 patients treated with abiraterone or enzalutamide, a multivariate analysis including tumor burden and TP53 status show no significant correlation between AR-V1, AR-V2… (full text at CIViC) PMID 30209161 · De Laere et al., 2019 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.